ProMetic gets $4.6M purchase order from Switzerland’s Octapharma

LAVAL, Que. – ProMetic Life Sciences Inc. (TSX:PLI) has received a $4.6-million purchase order under its supply agreement with Octapharma, a Swiss-based global plasma fractionation company that specializes in human proteins.

Shipments to Octapharma for the order are expected to exceed $2 million in the second half of 2012, ProMetic said Tuesday in a news release.

Get weekly money news

Get expert insights, Q&A on markets, housing, inflation, and personal finance information delivered to you every Saturday.

Sign up for weekly money newsletter Sign Up

By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

“This larger than originally anticipated purchase order from Octapharma for the second half of 2012 demonstrates the industry’s growing demand for safer and differentiating plasma derived products,” ProMetic president and CEO Pierre Laurin said.

The order relates to the purchase of PrioClear, ProMetic’s proprietary prion capture resin used in Octapharma’s manufacturing process for its plasma product, Octaplas. Octaplas is currently approved for marketing in several European countries and is awaiting regulatory approval for use in North America.

ProMetic is a biopharmaceutical company located in Laval, just north of Montreal. It has research and development facilities in the United Kingdom, the U.S. and Canada and manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle East.